Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Submits Application for ME2080 to Treat Dravet’s Syndrome
January 6, 2012
- Tivozanib Significantly Improves PFS Compared to Sorafenib in RCC: Astellas
January 6, 2012
- RaQualia Licenses COX-2 Inhibitor in China
January 5, 2012
- Takeda Voluntarily Recalls Bestcall IM Inj. 0.5 g
January 5, 2012
- Arena Submits Response to FDA CRL for Lorcaserin: Eisai
January 5, 2012
- CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
January 5, 2012
- SymBio Initiates PII Trials for Relapsed, Refractory Multiple Myeloma Treatment SyB L-0501
December 28, 2011
- Nippon Kayaku Starts Clinical Study for Remicade Biosimilar
December 28, 2011
- Sanofi-aventis Completes Patient Enrollment for Int’l ATLAS Study for Lantus
December 28, 2011
- 2 ARB/CCB Combination Products Enter Top 100 Sales Ranking in 1st Half of FY2011
December 28, 2011
- Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
- Ain Pharmaciez’s Generic Drug Wholesale Subsidiary Showing Steady Growth
December 28, 2011
- Fuji Pharma, Mochida Apply for Japan’s 1st G-CSF Biosimilar
December 27, 2011
- Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
December 27, 2011
- Novartis Receives Add’l Approval for Afinitor as 1st pNET Indication in Japan
December 27, 2011
- Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
- Sawai Pharmaceutical Wins Ebastine Patent Dispute
December 26, 2011
- JT to Introduce Anti-HIV Drug Booster from US Company
December 26, 2011
- Toray, JT, Torii Terminate Joint Development of Additional Indication for Nalfurafine
December 26, 2011
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…